Prosecution Insights
Last updated: April 19, 2026
Application No. 18/393,991

COSMETIC COMPOSITION

Non-Final OA §102§112
Filed
Dec 22, 2023
Examiner
DAVIS, BRIAN J
Art Unit
1614
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Ajinomoto Co., Inc.
OA Round
1 (Non-Final)
85%
Grant Probability
Favorable
1-2
OA Rounds
1y 11m
To Grant
80%
With Interview

Examiner Intelligence

Grants 85% — above average
85%
Career Allow Rate
1317 granted / 1549 resolved
+25.0% vs TC avg
Minimal -5% lift
Without
With
+-4.8%
Interview Lift
resolved cases with interview
Fast prosecutor
1y 11m
Avg Prosecution
47 currently pending
Career history
1596
Total Applications
across all art units

Statute-Specific Performance

§101
4.0%
-36.0% vs TC avg
§103
16.0%
-24.0% vs TC avg
§102
19.4%
-20.6% vs TC avg
§112
43.6%
+3.6% vs TC avg
Black line = Tech Center average estimate • Based on career data from 1549 resolved cases

Office Action

§102 §112
DETAILED ACTION Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Claim Objections Claim 9 is objected to because of the following informalities: the use of the term “…kinds…” renders the claim ungrammatical. The examiner respectfully suggests simply deleting the term. Appropriate correction is required. Claim 10 is objected to because of the following informalities: the use of the phrase “…kinds of…” renders the claim ungrammatical. The examiner respectfully suggests simply deleting the phrase. Appropriate correction is required. Claim Rejections - 35 USC § 112 The following is a quotation of 35 U.S.C. 112(b): (b) CONCLUSION.—The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the inventor or a joint inventor regards as the invention. The following is a quotation of 35 U.S.C. 112 (pre-AIA ), second paragraph: The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention. Claim 13 is rejected under 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which the inventor or a joint inventor (or for applications subject to pre-AIA 35 U.S.C. 112, the applicant), regards as the invention. A claim that simultaneously recites both a composition (“The composition according to claim 1…”) and an active method step for its use (“…is added…”) is indefinite. (An active method step requires an activity to actually occur as compared to a recitation of provisional language referring to something that could happen.) Note the discussion at MPEP 2173.05(p)(II). Claim Rejections - 35 USC § 102 In the event the determination of the status of the application as subject to AIA 35 U.S.C. 102 and 103 (or as subject to pre-AIA 35 U.S.C. 102 and 103) is incorrect, any correction of the statutory basis (i.e., changing from AIA to pre-AIA ) for the rejection will not be considered a new ground of rejection if the prior art relied upon, and the rationale supporting the rejection, would be the same under either status. The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action: A person shall be entitled to a patent unless – (a)(1) the claimed invention was patented, described in a printed publication, or in public use, on sale, or otherwise available to the public before the effective filing date of the claimed invention. Claims 1, 4, 7-10 and 18 are rejected under 35 U.S.C. 102(a)(1) as being clearly anticipated by (an apparent catalog reference from) Ajinomoto Heath Supply, Mintel, Deep Harmonize Emulsion, 2010, 3 pages, cited in the IDS. The reference teaches a cosmetic composition (page 2, Ingredients) comprising at least one polyaspartic acid or a salt thereof (sodium polyaspartate); zinc pyrrolidonecarboxylate (zinc PCA); and at least one aliphatic hydroxycarboxylic acid having 1-10 carbon atoms or a salt thereof (sodium citrate). The composition further comprises an alkali metal salt of pyrrolidonecarboxylic acid (sodium PCA); arginine; an acidic amino acid or its salt (glutamic acid); a basic amino acid other than arginine or its salt (lysine glutamate); a neutral amino acid or its salt (leucine, isoleucine); and polyhydric alcohols (butylene glycol, glycerin, dipropylene glycol). Claims 1, 4-6, 10 and 18 are rejected under 35 U.S.C. 102(a)(1) as being clearly anticipated by CN 111991261 A, whose English language machine translation has been relied upon for purposes of this Office Action and is cited in the IDS. The reference teaches shampoo formulations (i.e. cosmetic formulations) comprising 0.4-0.6 wgt. % of sodium polyaspartate, 0.3 wgt. % zinc pyrrolidonecarboxylate, and 0.5-0.6 wgt. % of citric acid (beginning at page 12, Embodiments 2 and 3, and Comparative Examples 1, 2, 5-7 and 9). The formulation of Comparative Example 5, for example, further comprises coco-glucoside (a polyhydric alcohol). Allowable Subject Matter Claims 2, 3, 11, 12, 14-17, 19 and 20 are objected to as being dependent upon a rejected base claim, but would be allowable if rewritten in independent form including all of the limitations of the base claim and any intervening claims. Conclusion Any inquiry concerning this communication or earlier communications from the examiner should be directed to BRIAN J DAVIS whose telephone number is (571)272-0638. The examiner can normally be reached M-F 8:30-5:00 PM EST. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Ali Soroush, can be reached at 571-272-9925. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /BRIAN J DAVIS/Primary Examiner, Art Unit 1614 1/19/2026
Read full office action

Prosecution Timeline

Dec 22, 2023
Application Filed
Jan 19, 2026
Non-Final Rejection — §102, §112 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12594226
COMPOSITION FOR AMELIORATING SKIN CONDITION
2y 5m to grant Granted Apr 07, 2026
Patent 12594257
MEANS AND METHODS FOR IMPROVING ANTI-TUMORAL EFFICACY OF TRANSMEMBRANE CHANNEL PROTEIN BLOCKERS
2y 5m to grant Granted Apr 07, 2026
Patent 12594242
LIPID COMPOUNDS AND LIPID NANOPARTICLE COMPOSITIONS
2y 5m to grant Granted Apr 07, 2026
Patent 12595280
PHOSPHORAMIDATES FOR THE TREATMENT OF HEPATITIS B VIRUS
2y 5m to grant Granted Apr 07, 2026
Patent 12576107
METHODS OF TREATING CHRONIC INFLAMMATORY DISEASES
2y 5m to grant Granted Mar 17, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

AI Strategy Recommendation

Get an AI-powered prosecution strategy using examiner precedents, rejection analysis, and claim mapping.
Powered by AI — typically takes 5-10 seconds

Prosecution Projections

1-2
Expected OA Rounds
85%
Grant Probability
80%
With Interview (-4.8%)
1y 11m
Median Time to Grant
Low
PTA Risk
Based on 1549 resolved cases by this examiner. Grant probability derived from career allow rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month